Fundamentally, IPAV is in the business of accelerating patient cures. Therefore, our team is excited by the opportunities presented by the US 21st Century Cures Act, which positively impacts all stakeholders in healthcare translation.
We are proud to report that key members of the IPAV Advisory Board and core team contributed to a thought provoking review of this critical legislature. Proving that healthcare regulation can be impactful and interesting, the piece compares the potential impact of the Act on 21st century healthcare to that of the Magna Carta on the foundation of global legal systems. Yet again proof that IPAV and it’s partners deliver healthcare transformation differently!
Importantly the piece highlights major incentives for medical device manufacturers, developers of companion diagnostics, bioprocessing optimisation and provision of risk:benefit analysis in randomised control trials. At IPAV we are actively supporting our clients in leveraging maximum benefit from these initiatives.
We look forward sharing our expertise to accelerate the translation of your healthcare innovation to patient benefit.